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Abstract  1 
BACKGROUND: The Mediterranean diet (MD) is widely recommended for the prevention of 2 
chronic disease, but evidence for a beneficial effect on bone health is lacking. 3 
OBJECTIVE: To examine the effect of a Mediterranean-like dietary pattern (NU-AGE diet) on 4 
indices of inflammation with a number of secondary endpoints, including BMD and 5 
biomarkers of bone and collagen degradation in a 1-y multi-center randomised controlled 6 
trial (RCT) (NU-AGE) in elderly Europeans. 7 
DESIGN: A RCT was undertaken across 5 European centers. Subjects in the intervention 8 
group consumed the NU-AGE diet for 1-y by receiving individually tailored dietary advice, 9 
coupled with supplies of foods such as wholegrain pasta, olive oil and a vitamin D3 10 
supplement (10 µg/day). Participants in the control group were provided with leaflets on 11 
healthy eating available in their country. 12 
RESULTS: 1294 participants (mean age 70.9 ± 4.0 y, 44% male) were recruited to the study 13 
and 1142 completed the 1-y trial. The Mediterranean-like dietary pattern had no effect on 14 
BMD (site specific or whole body); including compliance to the intervention in the statistical 15 
model did not change the findings. There was also no effect of the intervention on the 16 
urinary biomarkers, free pyridinoline or free deoxypyridinoline. Serum 25(OH)D significantly 17 
increased and PTH decreased (p<0.001) in the MD compared with the control group.  Sub-18 
group analysis of individuals with osteoporosis at baseline (site specific BMD T-score ≤ -2.5 19 
SD) showed that the MD attenuated the expected decline in femoral neck BMD (n=24 MD 20 
group, n=30 control group, p = 0.04) but had no effect on lumbar spine or whole body BMD. 21 
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CONCLUSIONS: A 1-y intervention of the Mediterranean-like diet together with vitamin D3 22 
supplements (10 µg/day) reduced the rate of loss of bone at the femoral neck in individuals 23 
with osteoporosis but had no effect on those with BMD in the normal range.  24 
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INTRODUCTION  42 
A Mediterranean dietary pattern (MD), widely recommended for the prevention of chronic 43 
disease, is characterized by a high intake of fruits, vegetables, nuts, unrefined cereals and 44 
olive oil, a moderately high intake of fish, a low-to-moderate intake of dairy products, a low 45 
intake of meat, and a moderate intake of alcohol (1, 2). Data from prospective cohort 46 
studies show that greater adherence to a MD is associated with a significant improvement 47 
in health status, including reduced total mortality (2) and reduced incidence of 48 
cardiovascular disease, cancer, Parkinson’s and Alzheimer’s disease (3). Randomised 49 
controlled trials confirm that the MD may protect against vascular disease, although the 50 
quantity and quality of evidence available is limited and highly variable (4).  51 
 52 
There are relatively few studies examining the association between a MD and bone health 53 
(bone mineral density and/or fracture incidence) and the available data are conflicting (5). A 54 
review of population-based studies, which focussed on fracture as an outcome (6), 55 
suggested that one of the modifiable risk factors for bone health is adherence to a MD. This 56 
conclusion was based on post-hoc analysis of longitudinal data from 93,676 women aged 57 
50-79 y at the start of the Women’s Health Initiative study which reported that higher 58 
adherence to a MD was associated with a lower risk for hip fractures (7). Data from 59 
randomized controlled trials investigating the effect of the MD on measures of bone health 60 
are sparse due to the difficulties of undertaking a dietary intervention that is long enough 61 
(i.e. minimum one year’s duration) to be able to detect changes in BMD. 62 
The aim of the present study was to examine the effect of the MD on BMD and biomarkers 63 
of bone and collagen degradation, as pre-specified secondary outcome measures, in a 1-y 64 
6 
 
Linking powered by eXtyles 
multi-center randomized controlled trial (NU-AGE) in elderly Europeans. The trial was 65 
designed to assess the effects of consuming a Mediterranean-like dietary pattern for 1-y on 66 
markers of inflammation as the primary outcome and a series of secondary health-related 67 
outcomes, which include BMD and biomarkers of bone and collagen degradation. The 68 
Mediterranean-like dietary pattern was tailored individually to complement habitual dietary 69 
patterns to maximise compliance.  70 
 71 
STUDY DESIGN AND METHODS  72 
The NU-AGE trial was conducted in five European centres (Bologna in Italy, Norwich in the 73 
United Kingdom, Wageningen in the Netherlands, Warsaw in Poland and Clermont Ferrand 74 
in France).  A detailed description of the European Commission-funded NU-AGE project has 75 
been reported elsewhere (8).   76 
 77 
Ethics approval  78 
Local ethical approval was provided by the Independent Ethics Committee of the 79 
Sant'Orsola-Malpighi Hospital Bologna (Italy), the National Research Ethics Committee – 80 
East of England (UK), the Wageningen University Medical Ethics Committee (Netherlands), 81 
the Bioethics Committee of the Polish National Food and Nutrition Institute (Poland) and 82 
South-East 6 Person Protection Committee (France).  All study procedures were in 83 
accordance with the ethical standards of the Helsinki Declaration. All participants gave 84 
informed consent before participating.  The trial was registered at clinicaltrials.gov 85 
(NCT01754012).   86 
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 87 
Participants  88 
Recruitment and selection criteria have been reported previously (9). Briefly, 1294 89 
participants aged 65–79 y were recruited through local advertisements, media publicity, and 90 
general practitioner surgeries between April 2012 and January 2014 at the five recruitment 91 
centres.  Study participants were free living and responsible for their own dietary choices.  92 
Ineligibility criteria included any clinically diagnosed chronic disease, use of corticosteroids 93 
or insulin medications, recent use of antibiotics or vaccinations, recent change in habitual 94 
medication, presence of food allergy or intolerance necessitating a special diet, presence of 95 
frailty according to the Fried criteria (10) or malnutrition (defined as BMI<18.5 kg/m2 or 96 
>10% weight loss in the previous six months).  Participants were randomly allocated to the 97 
intervention or control group (1:1 allocation ratio) after stratification by gender, age, frailty 98 
status (pre-frail or non-frail) and BMI.  Randomization was performed by entering the 99 
described variables of a subject into a computer program that automatically allocates and 100 
generates a unique ID-code. Participants were informed about their group after 101 
randomization. Technicians performing laboratory analysis were blinded to the group 102 
assignment, but researchers carrying out BMD measurements were not blinded because of 103 
practical impossibilities, including the fact that the participants themselves knew which 104 
group they were in and were in a position to discuss this with researchers whilst undergoing 105 
measurements. 106 
 107 
Dietary intervention 108 
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Participants randomised to the intervention group received individually tailored 109 
standardised dietary advice in order to meet the study dietary requirements, as described 110 
previously (9).  The NU-AGE food based dietary guidelines were based on nutrient reference 111 
values and food-based dietary recommendations for older adults from each of the five 112 
countries where the intervention took place, the modified MyPyramid for Older Adults, and 113 
nutrient requirements from the European Commission and the Institute of Medicine (9).  114 
The individually tailored dietary advice, either given face-to-face or by telephone by a 115 
trained dietician or research nutritionist, was administered nine times during the year and 116 
supported by mail or e-mail.  To aid compliance participants in the intervention group 117 
received commercially available foods to help them meet the dietary guidelines including 118 
wholegrain pasta, olive oil, low-fat low-salt cheese, and high-MUFA and high-PUFA 119 
margarine in all centres and frozen vegetable soup (in Italy only) and vitamin D3 120 
supplements.  Participants completed 3-day food diaries and returned unused vitamin D3 121 
supplements at months four and eight to evaluate follow-up adherence and use of the 122 
provided foods.  Participants randomised to the control group were asked to continue with 123 
their usual diet for the year and only received a generally available leaflet with national 124 
dietary guidance.   125 
 126 
Compliance to the study protocol in both the intervention and control groups was evaluated 127 
with seven-day food diaries at the start and end of the one-year intervention.  A scoring 128 
system was developed to measure adherence to the diet; sixteen dietary components were 129 
included, 12 for which the highest intakes were ideal (fruits, vegetables, legumes, low-fat 130 
dairyand cheese, fish, lean meat and poultry, nuts, eggs, olive oil, fluids and vitamin D 131 
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supplements), two for which moderate intake was ideal (wholegrains and alcohol) and two 132 
for which low intakes were ideal (salt and sweets). Each component was scored 133 
proportionally from zero to 10 and contributed equally to the final score, which ranged from 134 
0 to 160, with a higher score representing better adherence to the diet.  High compliers 135 
were defined as participants whose change in the NU-AGE Index was ranked in the top two 136 
quintiles and low compliers were those in the lowest two quintiles.   137 
 138 
Outcome assessment 139 
At baseline and after 1-y, trained nurses or researchers measured whole body BMD with the 140 
use of DXA according to standard protocols and training (Hologic Discovery Wi , Hologic, 141 
Bedford, MA (UK); Lunar iDXA, GE Health Care Madison, WI, USA, enCORETM 2011 software 142 
version 13.6 (Bologna, Italy); Discovery QDR®, Hologic Inc., USA, software version 3, 143 
(Clermont-Ferrand, France); Lunar Prodigy, GE Health Care, Madison, WI, USA, enCORETM 144 
2011 software version 13.6 (Wageningen, the Netherlands and Warsaw, Poland.  145 
Additionally, at three of the intervention sites (Italy, UK and Poland) BMD was assessed at 146 
predefined anatomical regions, including the lumbar spine (L1 to L4) and proximal femur 147 
(including total hip and femoral neck BMD).  Osteoporosis was defined as a T-score of ≤-2.5 148 
SD below peak bone mass (11). 149 
 150 
Measurements of urine fPYD and fDPD 151 
Free pyridinium crosslinks in urine were measured by liquid chromatography tandem mass 152 
spectrometry (LC-MS/MS), as described elsewhere (12). In brief, the LC-MS/MS method 153 
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quantified free pyridinoline (fPYD) and free deoxypyridinoline (fDPD) simultaneously from a 154 
single sample analysis. fPYD and fDPD were calibrated using commercial standards 155 
(Immundiagnostik, Bensheim, Germany), and acetylated pyridinoline as internal standard. 156 
Prior to LC-MS/MS analysis, a solid phase extraction procedure was carried out on urine 157 
samples pre-treated with hydrochloric acid. The acidified samples were extracted using 158 
cellulose packed columns and eluted with 0.2% heptafluoro-butyric acid (HFBA) in water. 159 
The inter- and intra-assay coefficient of variation (CV) were ≤9.9% between the assay 160 
working range of 2-200 nmol/L. fPYD and fDPD results obtained from LC-MS/MS analysis 161 
were adjusted against urine creatinine measurements, which was performed on the COBAS® 162 
C501 analyser (Roche, Burgess Hill, UK). The inter- and intra-assay CV was ≤3.1% across the 163 
assay working range (375-55000 µmol/L). 164 
 165 
Measurement of serum 25-dihyroxyvitamin D and parathyroid hormone 166 
Concentrations of total 25-hydroxyvitamin D (25(OH)D) [i.e. 25(OH)D2 plus 25(OH)D3] in all 167 
serum samples were measured at the laboratory of the Cork Centre for Vitamin D and 168 
Nutrition Research using a slightly modified version of the LC-MS/MS method that has been 169 
described in detail elsewhere (13) and is certified by the Centers for Disease Control and 170 
Prevention’s (CDC) Vitamin D Standardization Certification Program (14). The modifications 171 
were effected so as to reduce the total run time per sample from 10 mins in our existing 172 
method to 7 mins in the current method thereby increasing our efficiency of analysis of the 173 
sample loads (see Supplemental Table 1 for details of gradient and multiple reaction 174 
monitoring (MRM) parameters).  The 3-epimer of 25-hydroxyvitamin D3 was 175 
chromatographically resolved from 25(OH)D3, and the isotopically labelled d3-3-epi-176 
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25(OH)D3 was used as an internal standard to verify retention time and separation of 3-epi-177 
25(OH)D3 and 25(OH)D3 in each sample run.  The mean intra-and inter-assay CVs of the 178 
methods were 3.9% and 6.5%, respectively, for 25(OH)D3 (using low, medium and high 179 
concentrations of 33.5, 49.2 and 86.2 nmol/L, respectively). The mean intra-assay and inter-180 
assay CVs of the method were 12% and 7.1%, respectively, for 25(OH)D2 (using low, medium 181 
and high concentrations of 1.10, 6.57 and 13.9 nmol/L, respectively).  182 
 183 
Serum parathyroid hormone (PTH) concentrations were measured at the Cork Centre for 184 
Vitamin D and Nutrition Research in all serum samples with the use of an ELISA (intact PTH; 185 
MD Biosciences Inc.) Intra-assay and inter- assay CVs were 3.0% and 5.1%, respectively (at a 186 
concentration of 47.7 and 52.6 pg/ml, respectively). 187 
 188 
Statistical analysis  189 
The power calculation for the estimation of the required sample size for this trial was based 190 
on a change in CRP (as the primary outcome measure) of 0.6 mg/L (SD 4), which required a 191 
sample size of 1000 participants (two-sided, 80% power and 0.05 alpha).  We increased this 192 
number to 1250 to account for an anticipated dropout rate of 20%.  A previous study 193 
examining the effect of a dietary intervention and consumption of fortified dairy products 194 
for 12 months on spine BMD in postmenopausal women observed changes of -0.045 g/cm2 195 
in the control group, 0.008 g/cm2 in the calcium supplemented group and 0.053 g/cm2 in the 196 
dietary intervention group (15).  Based on these data we would need 36 participants (18 per 197 
group) to observe an effect on spinal BMD (two-sided, 99% power and 0.05 alpha).  This 198 
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indicated that we had sufficient osteoporotic participants (see Table 2) in our study to 199 
conduct stratified analysis on the effect of MD on BMD. 200 
 201 
The normality of the data for each variable was tested using Kolmogorov-Smirnov Test and 202 
the Shapiro-Wilk Test. Baseline characteristics are presented as mean SD or n (%) for 203 
categorical variables, and baseline between-group differences were assessed using 204 
independent sample t-tests or χ2 tests.  The effect of the intervention on changes in BMD 205 
and bone biomarkers was assessed using linear mixed-effect models with participant 206 
included as random effect, time, treatment group, time x treatment group interaction, and 207 
the explanatory variables study centre, age, sex, baseline BMI, baseline calcium intakes and 208 
baseline 25(OH)D were included.  Where we observed a significant time*treatment 209 
interaction we also tested if there was a study centre effect by including a three way 210 
time*treatment*study centre interaction term in the model.  For each variable, values <3 or 211 
>3 SDs from the mean were considered outliers and removed.  As data were not normally 212 
distributed, the models were fitted on a log-transformed scale.  To account for multiple 213 
testing we applied a Bonferroni correction, with eight tests per group (three BMD measures 214 
and five biomarkers).  We calculated the site-adjusted mean difference in intake of dietary 215 
components associated with bone health using ANCOVA. Data were analysed using Stata 216 
version 14 (Stata Corp., College Station, TX, USA).   217 
 218 
RESULTS  219 
Of the 1294 participants recruited to the NU-AGE study n=1142 completed (11.7% drop out 220 
rate) (Supplemental Figure 1).  Of these completers, n=562 in the control group and n=555 221 
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in the intervention group had whole-body DXA scans at baseline and follow-up and 222 
complete covariate data (97.8%).  There were no significant differences in baseline 223 
characteristics between the two groups (Table 1).  Osteopenia (defined as a lumbar spine T-224 
score of <-1.5 SD below peak bone mass) was present in 37%, and osteoporosis (defined as 225 
a lumbar spine T-score of <-2.5 SD below peak bone mass) in 8% of participants at baseline. 226 
 227 
After 1-y dietary intervention, there was no effect on BMD at any bone site (Table 2) or on 228 
the concentrations of urinary fDPD and fPYD or the fDPD: fPYD ratio (Table 3).  There was a 229 
significant (p<0.001) time x treatment interaction in change in serum 25(OH)D over the 12 230 
months (Table 3), where the mean concentration significantly increased in the intervention 231 
group (4.5 ng/mL; 95% CI 3.9, 5.1) but was unchanged in the control group (0.5 ng/mL; 232 
95%CI -0.1, 1.0) (p<0.01).  There was a significant (p<0.001) time x treatment interaction in 233 
change in serum PTH over the 12 months, where the mean concentration increased in the 234 
control group (3.9 pg/mL 95% CI 2.1, 5.6) but no significant change in the intervention group 235 
(-1.4 pg/mL 95% CI -3.1, 0.4) (p<0.001)(Table 3).  There was no effect of study centre for 236 
serum 25(OH)D (P=0.049) or serum PTH (P=0.755).     237 
 238 
When examining the sub-group of participants diagnosed with osteoporosis at baseline 239 
(n=54) there was a 0.9% difference between the groups in the change in femoral neck BMD 240 
(Table 2); BMD increased in the intervention group (0.008 g/cm2 95% CI -0.001,0.018) and 241 
decreased in the controls (-0.009 g/cm2 95%CI -0.018,-0.001)  P=0.04).  No effect of study 242 
centre was observed (P=0.415).  The intervention had no effect on BMD measured at the 243 
lumbar spine or the whole body.   244 
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 245 
When examining changes in specific dietary components associated with bone health we 246 
observed a significant increase in intakes of olive oil, low fat dairy and calcium in the 247 
intervention group relative to controls (Figure 2).  248 
 249 
DISCUSSION  250 
In one of the first long-term intervention studies examining the effect of the MD on BMD, 251 
we have found that consuming a MD with 10 µg/day vitamin D3 reduces the rate of femoral 252 
neck bone loss, but not total body or spinal BMD loss, in elderly people with osteoporosis. 253 
There were no beneficial changes in BMD in individuals with BMD in the normal range at 254 
baseline.  255 
 256 
There is conflicting evidence from cross-sectional studies examining the association 257 
between the MD and BMD, and a lack of consistency regarding the BMD sites which are 258 
most affected. In Chinese adults aged 40-75y, higher scores for adherence to a MD, adapted 259 
for China, were positively and dose-dependently associated with higher BMDs at whole 260 
body, lumbar spine, total hip, femur neck, trochanter, intertrochanter, but not Ward’s 261 
triangle area (2.41–3.96% higher, quintile 5 vs. quintile 1, all P-values < 0.001), after 262 
adjusting for age and gender (16). Higher intakes of whole grains, fruits, and nuts and a 263 
lower intake of red and processed meat were independently associated with higher levels of 264 
BMD at several bone sites, but vegetables, legumes, fish, monounsaturated fat/saturated 265 
fat ratio, and moderate alcohol consumption showed no independent associations with 266 
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BMD in this study. In Finnish women aged 65-71 y (17) lumbar spine, femoral neck and total 267 
BMD were not significantly different across the Baltic sea diet (BSD) or MD quartiles. Also, 268 
there were no significant associations of BSD and MD quartiles in the subgroup with 269 
osteoporosis.  A study of 220 Greek women (mean age 48 ± 12 y) found no link between 270 
adherence to a MD and bone mass, but when Principal Components Analysis was used to 271 
differentiate 10 dietary patterns, a high consumption of fish and olive oil and low intake of 272 
red meat was positively associated with lumbar spine BMD (18). A study in 200 pre- and 273 
post-menopausal Spanish women showed that a higher habitual intake of fruits, vegetables 274 
and nuts was associated with higher total body BMD in post-menopausal women (19).  A 275 
smaller study in 87 Italians aged 70.1 ± 4.9 y also showed that adherence to the MD was 276 
associated with a higher BMD (T score assessed by calcaneal quantitative ultrasound of the 277 
mid-calcaneus) with lowest adherence observed in the 15% osteoporotic subjects (20).  278 
 279 
Although it is not possible to draw conclusions about cause and effect from cross-sectional 280 
data, an association between the MD, or some components of the diet, and bone health is 281 
reported in some studies. To our knowledge, no previous dietary intervention studies in 282 
elderly people have reported the effect of the MD on BMD, therefore the NU-AGE 283 
randomized controlled trial provides an important opportunity to clarify the relationship. 284 
Our multi-center trial results show that consuming a MD (together with vitamin D 285 
supplements) for a year had no effect on BMD (whole body or site specific) in older people, 286 
and even when we included the degree of compliance to the dietary change in the statistical 287 
model this did not change the findings (Supplemental Table 2). Sub-group analysis, 288 
however, showed a significant beneficial effect of the MD plus supplemental vitamin D3 on 289 
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femoral neck (but not lumbar spine or whole body) BMD in subjects identified at baseline as 290 
having osteoporosis. 291 
 292 
Phenolic compounds, as found in virgin olive oil, are suggested as one of the components of 293 
the MD responsible for the effect on bone; the proposed mechanism is modulation of the 294 
proliferative capacity and cell maturation of osteoblasts through increased alkaline 295 
phosphatase activity and deposition of calcium ions in the extracellular matrix (21). A 296 
randomized controlled trial reported that the consumption of a MD enriched with virgin 297 
olive oil for 2 y was associated with an increase in the bone biomarkers for bone formation, 298 
serum osteocalcin and procollagen 1 N-terminal propeptide (P1NP) concentrations, in 299 
elderly men (22), indicating that the MD increases bone formation rather than decreasing 300 
resorption. In our dietary intervention, we provided virgin olive oil to the intervention group 301 
to encourage subjects to consume more olive oil.  Baseline olive oil intake was highest in 302 
Italy (9.6 ± 0.4 g/d) and lowest in France (2.1 ± 0.4 g/d) and although there were no 303 
significant differences in intake between the countries, the greatest changes in intakes were 304 
observed in France (6.0 g/d) and the lowest in Italy (1.0 ± 0.5 g/d).   A reduction in sodium 305 
intake, as undertaken in the DASH diet study (23), may be one of the consequences of 306 
consuming a MD (with reduced processed meat intake, and increased intakes of fruits and 307 
vegetables), and this has been reported to have beneficial effects on bone health through a 308 
reduction in urinary calcium excretion (24). However, knowing the difficulties of accurately 309 
measuring sodium intake, we did not attempt to evaluate the effect of sodium intake on 310 
BMD. Similarly, for other dietary components that may impact on bone turnover, such as 311 
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vitamin K, we were unable to include them in our model due to the lack of reliable intake 312 
data. 313 
    314 
Although osteoporosis is assumed to be a risk factor for bone fracture, the evidence for a 315 
protective effect of the MD on risk of fracture is conflicting. Post-hoc analysis of longitudinal 316 
data (median follow-up time of 15.9 y) from the US Women’s Health Initiative reported a 317 
lower risk for hip (but not total) fractures with higher adherence to a Mediterranean diet in 318 
women 50-79 y (7). Conversely, a smaller population-based study of shorter duration (8 y) in 319 
France found that greater adherence to the MD was not associated with a decreased risk of 320 
fractures in men and women aged 67 y on recruitment (25). In a prospective study in 321 
European men and women (EPIC) with a mean age of 48.6 y, followed for a median of 9 y, 322 
increased adherence to MD protected against hip fracture occurrence, particularly among 323 
men (26). In the PREDIMED trial, an observational cohort study nested in the main trial, 324 
found that a higher consumption of extra-virgin olive oil was associated with a lower risk of 325 
osteoporosis related fractures in Mediterranean men and women, aged 55-80 y, at high 326 
cardiovascular risk (21). As with the cross-sectional studies cited above, the effect of the MD 327 
appears to be mediated through particular dietary components, such as virgin olive oil. 328 
 329 
In our study, subjects in the intervention group were given vitamin D3 supplements (10 330 
µg/day), which significantly increased serum total 25(OH)D and reduced parathyroid 331 
hormone concentrations in the whole intervention group (but not in the osteoporosis sub-332 
group) compared with the control group (Table 3). This may be a question of insufficient 333 
power as the osteoporotic sub-group was small. In this combined intervention design it is 334 
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not possible to disentangle the relative influence of the MD and/or vitamin D on femoral 335 
neck BMD in osteoporotic subjects. However, it is likely that the daily dose of vitamin D3 (10 336 
µg)  was too low to have a significant impact on bone loss. MacDonald et al (27) found that 337 
hip bone loss was attenuated when vitamin D 3 supplements of 1000 IU (25µg) were given 338 
daily for 1-y to postmenopausal women, but 400 IU (10 µg) had no effect. A systematic 339 
review of vitamin D supplementation and risk of fractures concluded that vitamin D 340 
supplements of 700-800 IU (17.5-20 µg) per day appears to reduce the risk of hip and any 341 
non-vertebral fractures in ambulatory or institutionalized elderly persons, but that a vitamin 342 
D dose of 400 IU (10 µg) per day is not sufficient for fracture prevention (28).   It is also 343 
worth noting that the baseline serum 25(OH)D of the participants in this RCT at ~25 ng/ml, 344 
exceeded that suggested by the Institute of Medicine (i.e., 20 ng/mL) as covering the needs 345 
of nearly all individuals from a bone health perspective (29).  The Endocrine Society, 346 
however, have suggested that to maximize the effect of vitamin D on calcium, bone, and 347 
muscle metabolism, the circulating 25(OH)D should be above 30 ng/ml (30).  This latter 348 
threshold was only achieved in just under half of the intervention group in the present RCT 349 
(mean serum 25(OH)D at endpoint, 29 ng/ml).    350 
The strength of this study is that it was a long-term (one year) RCT carried out in a relatively large 351 
number (over 1,000) of European men and women, designed to examine the effects of a 352 
Mediterranean-like diet on various health parameters, including bone health. One of the limitations 353 
is the relatively small size of the sub-group with osteoporosis, and the significant and interesting 354 
findings of differences in response between individuals with BMD in the normal range and those 355 
with osteoporosis needs to be verified in a future study.  356 
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In conclusion, our study showed that a 1-y intervention of the MD together with vitamin D3 357 
supplements (10µg/day) reduced the rate of loss of bone at the femoral neck in individuals 358 
with osteoporosis but had no effect on those with BMD in the normal range.  359 
 360 
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Table 1: Baseline characteristics of the NU-AGE study participants according to 
intervention group  
 
Characteristic Intervention diet Control diet P= 
Sex, female n=632 363 (57.4) n=644 356 (55.3) 0.437 
Age, y n=632 70.7 ± 4.1 n=643 71.1 ± 3.9 0.046 
Body mass index, kg/m2 n=633 26.9 ± 4.2 n=643 26.7 ± 3.8 0.492 
Calcium intakes, g/d n=618 618 ± 912 n=622 895 ± 347 0.361 
Lumbar spine BMD, g/cm2 n=377 1.1 ± 0.2 n=379 1.1± 0.2 0.553 
Femoral neck BMD, g/cm2 n=379 0.8 ± 0.1 n=385 0.8 ± 0.1 0.328 
Whole body BMD, g/cm2 n=616 1.1 ± 0.1 n=621 1.1 ± 0.1 0.963 
Osteoporosis, yes n=377 27 (7.2) n=380 37 (9.7) 0.370 
Free Pyridinoline (fPYD), 
creatinine adjusted nmol/mmol n=612 24.0 ± 7.3 n=620 24.3 ± 7.5 0.489 
Free Deoxypyridinoline (fDPD), 
creatinine adjusted nmol/mmol n=612 6.1 ± 1.9 n=619 6.2 ± 2.0 0.636 
deoxypyridinoline to 
Pyridinoline ratio  n=612 0.3 ± 0.1 n=619 0.3 ± 0.1 0.180 
Parathyroid hormone, pg/ml n=483 44.3 ± 26.5 n=479 42.4 ± 23.6 0.223 
25-hydroxyvitamin D, ng/ml n=613 24.6 ± 9.1 n=619 24.8 ± 8.9 0.745 
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Table 2: Mean difference in bone mineral density after 1-y of follow-up in the intervention 
and control diet groups 
 
 




Lumbar spine BMD, g/cm2 n=338 n=325  
  Baseline 1.060 (1.042,1.078) 1.045 (1.026,1.063)  
  1-y 1.065 (1.047,1.084) 1.049 (1.030,1.067)  
  Change 0.005 (0.002,0.009) 0.004 (0.000,0.007) 1.000 
Femoral neck BMD, g/cm2 n=342 n=326  
  Baseline 0.820 (0.807,0.833) 0.809 (0.796,0.822)  
  1-y 0.816 (0.804,0.829) 0.804 (0.791,0.817)  
  Change -0.004 (-0.006,-0.001) -0.005 (-0.008,-0.002) 1.000 
Whole body BMD, g/cm2 n=551 n=557  
  Baseline 1.099 (1.090,1.107) 1.092 (1.084,1.101)  
  1-y 1.098 (1.089,1.106) 1.091 (1.082,1.099)  




Lumbar spine BMD, g/cm2 n=25 n=33  
  Baseline 0.770 (0.743,0.797) 0.768 (0.745,0.791)  
  1-y 0.782 (0.755,0.810) 0.779 (0.755,0.802)  
  Change 0.012 (0.001,0.024) 0.011 (0.001,0.021) 1.000 
Femoral neck BMD, g/cm2 n=24 n=30  
  Baseline 0.649 (0.624,0.673) 0.635 (0.614,0.656)  
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  1-y 0.657 (0.633,0.681) 0.625 (0.605,0.646)  
  Change 0.008 (-0.001,0.018) -0.009 (-0.018,-0.001) 0.040 
Whole body BMD, g/cm2 n=20 n=22  
  Baseline 0.883 (0.867,0.899) 0.856 (0.841,0.870)  
  1-y 0.885 (0.869,0.901) 0.860 (0.846,0.875)  
  Change 0.002 (-0.004,0.008) 0.005 (-0.001,0.011) 1.000 
 
Values are mean (95% CI) adjusted for study centre, age, sex, calcium intakes, use of vitamin 
D supplements, 25-hydroxyvitamin D levels and BMI (all measured at baseline).  Participants 
were excluded from the analysis if outcome values were <3 or >3 SDs from the mean; 1P = 
Bonferroni corrected p values for the time x treatment interaction.  2Osteoporosis was 
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Table 3: Mean difference in bone biomarkers after 1-y of follow-up in the intervention and 
control diet groups 
 
Intervention Control P1 
Free Pyridinoline, nmol/mmol n=551 n=563  
  Baseline 23.1 (22.6,23.7) 23.6 (23.0,24.1)  
  1-y 23.6 (23.1,24.2) 23.6 (23.1,24.2)  
  Change 0.5 (0.0,1.0) 0.1 (-0.4,0.6) 1.000 
Free Deoxypyridinoline, 
nmol/mmol n=551 n=560  
  Baseline 5.88 (5.74,6.01) 6.02 (5.88,6.15)  
  1-y 5.99 (5.85,6.12) 5.93 (5.80,6.07)  
  Change 0.1 (0.0,0.2) -0.1 (-0.2,0.0) 0.208 
Free Deoxypyridinoline: free 
pyridinoline ratio n=554 n=563  
  Baseline 0.26 (0.25,0.26) 0.25 (0.25,0.26)  
  1-y 0.25 (0.25,0.26) 0.25 (0.25,0.26)  
  Change 0.00 (-0.01,0.00) 0.00 (-0.01,0.00) 1.000 
Parathyroid hormone, pg/ml n=468 n=467  
  Baseline 40.7 (38.7,42.8) 38.5 (36.5,40.5)  
  1-y 39.4 (37.3,41.4) 42.4 (40.2,44.5)  
  Change -1.4 (-3.1,0.4) 3.9 (2.1,5.6) 0.000 
25-hydroxyvitamin D, ng/ml n=548 n=562  
  Baseline 24.6 (24.0,25.3) 24.1 (23.5,24.8)  
  1-y 29.1 (28.4,29.8) 24.6 (24.0,25.2)  
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Free Pyridinoline, nmol/mmol n=24 n=30  
  Baseline 24.0 (21.7,26.4) 23.9 (21.8,26.0)  
  1-y 25.6 (23.2,28.0) 24.9 (22.8,27.0)  
  Change 1.6 (-0.6,3.8) 1.0 (-1.1,3.1) 1.000 
Free Deoxypyridinoline, 
nmol/mmol n=24 n=30  
  Baseline 6.69 (5.96,7.43) 6.30 (5.66,6.94)  
  1-y 6.44 (5.72,7.16) 6.76 (6.10,7.43)  
  Change -0.3 (-0.9,0.4) 0.5 (-0.2,1.1) 1.000 
Free Deoxypyridinoline: free 
pyridinoline ratio n=24 n=30  
  Baseline 0.28 (0.25,0.30) 0.26 (0.24,0.28)  
  1-y 0.26 (0.23,0.28) 0.27 (0.25,0.29)  
  Change -0.02 (-0.05,0.00) 0.01 (-0.01,0.03) 0.192 
Parathyroid hormone, pg/ml n=19 n=24  
  Baseline 44.4 (33.9,54.9) 43.0 (34.0,52.0)  
  1-y 44.4 (34.2,54.5) 49.0 (39.4,58.5)  
  Change 0.0 (-11.0,11.0) 6.0 (-2.4,14.4) 1.000 
25-hydroxyvitamin D, ng/ml n=23 n=29  
  Baseline 23.9 (20.9,27.0) 24.3 (21.6,27.1)  
  1-y 29.2 (25.8,40.2) 28.1 (25.2,31.1)  
  Change 5.2 (1.7,8.8) 3.8 (0.7,6.9) 1.000 
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Values are mean (95% CI) adjusted for study centre, age, sex, calcium intakes, use of vitamin 
D supplements, 25-hydroxyvitamin D levels and BMI (all measured at baseline).  Participants 
were excluded from the analysis if outcome values were <3 or >3 SDs from the mean;     
P1= Bonferroni corrected p values for the time x treatment interaction.  2Osteoporosis was 
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Figure legend 
 
Figure 1. Mean difference in intake of dietary components associated with bone health after 
1-y of follow-up in the intervention and control diet groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
